gsk201310106k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending October 2013
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1566.36 pence per Share on 7 October 2013, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 3 October 2013.
| |
Ordinary Shares
|
|
Sir Andrew Witty
|
878.465
|
|
Dr M M Slaoui
|
239.911
|
|
Mr S M Bicknell
|
145.117
|
|
Mr R G Connor
|
39.290
|
|
Mr S A Hussain
|
1,144.938
|
|
Mr D S Redfern
|
347.249
|
|
Ms C Thomas
|
386.704
|
|
Mr P C Thomson
|
114.758
|
|
Dr P J T Vallance
|
351.001
|
|
Ms E Walmsley
|
153.396
|
|
Mr C Weber
|
352.131
|
The Company was advised of this information on 9 October 2013.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
10 October 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October 10, 2013
By: SIMON BICKNELL
------------------
Simon Bicknell
Authorised Signatory for and on
behalf of GlaxoSmithKline plc